Providence Health and Services
  Home  |  Health Plans  |  Providers  |  Programs & Services  |  Hospitals & Clinics  |  Health Info  |  Employment  |  Foundations

Site Search
myProvidence:
Login
Register
 
 

 

Robert W. Franz Cancer Research Center

 

in the Earle A. Chiles Research Institute

Walter Urba sittingWalter J. Urba, M.D., Ph.D., directs the Robert W. Franz Cancer Research Center's efforts to find new treatments for cancer patients. Founded in 1993 by Dr. Urba and a team of internationally recognized scientists, the Franz Cancer Research Center today garners more than $2 million annually in federal grants and has a research staff of 60. Research space will more than double with the opening of the new 11-story Providence Cancer Center building on the Providence Portland Medical Center campus in February 2008.

By design, laboratories are physically near patient rooms so that scientists never lose sight of the people their research is intended to serve. This environment encourages translational research, which is so important to the development of new therapies for patients with cancer.

  • Read a welcome message from Walter J. Urba, M.D., Ph.D., medical director of the Robert W. Franz Cancer Research Center.

More Information


About our research|   Contact us
Cancer research laboratories|   Tours
Clinical research programs|   Earle A. Chiles Research Institute
Clinical trials|Foundation and community support
Employment opportunities   

News & Events

Providence Health & Services announces new region-wide medical research initiative

Walter Urba, M.D., Ph.D., Albert Starr, M.D., and Calvin Harrison will lead expanded research efforts to develop new treatments for cancer, cardiac and vascular disease, and neurological disorders.

Andrew Weinberg, Ph.D., receives grant to continue OX40 research

The National Institutes of Health (NIH)  has awarded Andrew Weinberg, Ph.D., chief of the Laboratory of Basic Immunology, a $1,350,000 grant over five years to continue his work on studying OX40.

Providence offers immunotherapy clinical trial in partnership with Duke University

Todd Crocenzi, M.D., director of Providence's Gastrointestinal Cancer Program, is site investigator in a multicenter, randomized phase II study of vaccine-induced active immunotherapy with PANVAC (viral vector) or autologous, cultured dendritic cells infected with PANVAC.